Efficacy outcomes by subgroup
Age <65 y (n = 64) | Age ≥65 y (n = 22) | |
ORR | 90.6 (80.7-96.5) | 63.6 (40.7-82.8) |
CR | 82.8 (71.3-91.1) | 63.6 (40.7-82.8) |
Median DOR, mo | 30.6 (23.1-NE) | NE (5.3-NE) |
Median PFS, mo | 33.0 (20.3-NE) | NE (2.9-NE) |
36-mo OS | 73.8 (60.7-83.0) | 80.0 (54.9-92.0) |
Bulky tumor(LDi ≤5 cm) (n = 49) | Bulky tumor (LDi >5 cm) (n = 37) | |
ORR | 85.7 (72.8-94.1) | 81.1 (64.8-92.0) |
CR | 77.6 (63.4-88.2) | 78.4 (61.8-90.2) |
Median DOR, mo | NE (16.5-NE) | NE (23.1-NE) |
Median PFS, mo | NE (16.8-NE) | 27.7 (16.4-NE) |
36-mo OS | 75.3 (59.7-85.5) | 74.1 (56.1-85.6) |
Classic histology (n = 68) | Blastoid histology (n = 12) | |
ORR | 86.8 (76.4-93.8) | 66.7 (34.9-90.1) |
CR | 79.4 (67.9-88.3) | 66.7 (34.9-90.1) |
Median DOR, mo | 30.2 (19.5-NE) | 30.6 (7.2-NE) |
Median PFS, mo | 27.8 (16.8-NE) | 25.0 (2.5-NE) |
36-mo OS | 77.5 (64.8-86.0) | 50.0 (20.8-73.6) |
Ki67 ≤30% (n = 50) | Ki67 >30% (n = 34) | |
ORR | 94.0 (83.5-98.7) | 70.6 (52.5-84.9) |
CR | 90.0 (78.2-96.7) | 61.8 (43.6-77.8) |
Median DOR, mo | NE (NE-NE) | 16.3 (13.7-30.2) |
Median PFS, mo | NE (NE-NE) | 16.6 (5.3-19.4) |
36-mo OS | 87.0 (73.3-94.0) | 55.6 (36.5-71.1) |
Prior lines of therapy = 1 (n = 26) | Prior lines of therapy >1 (n = 60) | |
ORR | 92.3 (74.9-99.1) | 80.0 (67.7-89.2) |
CR | 92.3 (74.9-99.1) | 71.7 (58.6-82.5) |
Median DOR, mo | NE (16.5-NE) | 30.6 (19.5-NE) |
Median PFS, mo | NE (19.4-NE) | 26.5 (16.6-NE) |
36-mo OS | 92.0 (71.6-97.9) | 67.0 (52.7-77.8) |
Nonrefractory (n = 41) | Refractory (n = 45) | |
ORR | 82.9 (67.9-92.8) | 84.4 (70.5-93.5) |
CR | 73.2 (57.1-85.8) | 82.2 (67.9-92.0) |
Median DOR, mo | 30.2 (16.2-NE) | NE (24.9-NE) |
Median PFS, mo | 27.7 (16.6-NE) | NE (16.8-NE) |
36-mo OS | 67.9 (50.4-80.4) | 80.9 (65.3-90.0) |
TP53 WT (n = 39) | TP53 mutation (n = 15) | |
ORR | 89.7 (75.8-97.1) | 80.0 (51.9-95.7) |
CR | 82.1 (66.5-92.5) | 66.7 (38.4-88.2) |
Median DOR, mo | NE (25.1-NE) | 13.7 (2.7-NE) |
Median PFS, mo | NE (19.4-NE) | 14.7 (2.9-NE) |
36-mo OS | 85.8 (69.1-93.9) | 57.1 (27.5-78.5) |
Age <65 y (n = 64) | Age ≥65 y (n = 22) | |
ORR | 90.6 (80.7-96.5) | 63.6 (40.7-82.8) |
CR | 82.8 (71.3-91.1) | 63.6 (40.7-82.8) |
Median DOR, mo | 30.6 (23.1-NE) | NE (5.3-NE) |
Median PFS, mo | 33.0 (20.3-NE) | NE (2.9-NE) |
36-mo OS | 73.8 (60.7-83.0) | 80.0 (54.9-92.0) |
Bulky tumor(LDi ≤5 cm) (n = 49) | Bulky tumor (LDi >5 cm) (n = 37) | |
ORR | 85.7 (72.8-94.1) | 81.1 (64.8-92.0) |
CR | 77.6 (63.4-88.2) | 78.4 (61.8-90.2) |
Median DOR, mo | NE (16.5-NE) | NE (23.1-NE) |
Median PFS, mo | NE (16.8-NE) | 27.7 (16.4-NE) |
36-mo OS | 75.3 (59.7-85.5) | 74.1 (56.1-85.6) |
Classic histology (n = 68) | Blastoid histology (n = 12) | |
ORR | 86.8 (76.4-93.8) | 66.7 (34.9-90.1) |
CR | 79.4 (67.9-88.3) | 66.7 (34.9-90.1) |
Median DOR, mo | 30.2 (19.5-NE) | 30.6 (7.2-NE) |
Median PFS, mo | 27.8 (16.8-NE) | 25.0 (2.5-NE) |
36-mo OS | 77.5 (64.8-86.0) | 50.0 (20.8-73.6) |
Ki67 ≤30% (n = 50) | Ki67 >30% (n = 34) | |
ORR | 94.0 (83.5-98.7) | 70.6 (52.5-84.9) |
CR | 90.0 (78.2-96.7) | 61.8 (43.6-77.8) |
Median DOR, mo | NE (NE-NE) | 16.3 (13.7-30.2) |
Median PFS, mo | NE (NE-NE) | 16.6 (5.3-19.4) |
36-mo OS | 87.0 (73.3-94.0) | 55.6 (36.5-71.1) |
Prior lines of therapy = 1 (n = 26) | Prior lines of therapy >1 (n = 60) | |
ORR | 92.3 (74.9-99.1) | 80.0 (67.7-89.2) |
CR | 92.3 (74.9-99.1) | 71.7 (58.6-82.5) |
Median DOR, mo | NE (16.5-NE) | 30.6 (19.5-NE) |
Median PFS, mo | NE (19.4-NE) | 26.5 (16.6-NE) |
36-mo OS | 92.0 (71.6-97.9) | 67.0 (52.7-77.8) |
Nonrefractory (n = 41) | Refractory (n = 45) | |
ORR | 82.9 (67.9-92.8) | 84.4 (70.5-93.5) |
CR | 73.2 (57.1-85.8) | 82.2 (67.9-92.0) |
Median DOR, mo | 30.2 (16.2-NE) | NE (24.9-NE) |
Median PFS, mo | 27.7 (16.6-NE) | NE (16.8-NE) |
36-mo OS | 67.9 (50.4-80.4) | 80.9 (65.3-90.0) |
TP53 WT (n = 39) | TP53 mutation (n = 15) | |
ORR | 89.7 (75.8-97.1) | 80.0 (51.9-95.7) |
CR | 82.1 (66.5-92.5) | 66.7 (38.4-88.2) |
Median DOR, mo | NE (25.1-NE) | 13.7 (2.7-NE) |
Median PFS, mo | NE (19.4-NE) | 14.7 (2.9-NE) |
36-mo OS | 85.8 (69.1-93.9) | 57.1 (27.5-78.5) |
NE, not estimable.